arrow
M

Mark W. Douglas

University of Sydney
H指数:35
被引数:3,889

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Elebsiran and PEG-IFNα for chronic hepatitis B infection: a partially randomized, open-label, phase 2 trial

Elbsiran和PEG-IFNα用于慢性乙型肝炎感染:一项部分随机、开放标签、II期试验

2025-11-070
OAAI
Safety and efficacy of REP 2139-Mg in patients with HDV-related advanced liver disease in an international compassionate access program

REP 2139-Mg在HDV相关晚期肝病患者的国际同情用药项目中的安全性与有效性

2025-11-060
PRE
Twelfth scientific biennial meeting of the Australasian Virology Society: AVS12 2024

第十二届澳大拉西亚病毒学会科学双年会议:AVS12 2024

2025-05-200
OA
Novel digital droplet inverse PCR assay shows that natural clearance of hepatitis B infection is associated with fewer viral integrations

新型数字液滴反向PCR检测方法表明,乙型肝炎病毒感染的自然清除与病毒整合较少相关。

2025-01-130
OA
Bivalent Omicron BA.1 vaccine booster increases memory B cell breadth and neutralising antibodies against emerging SARS-CoV-2 variants

二价Omicron BA.1疫苗加强剂增加记忆b细胞宽度并中和针对新兴SARS-CoV-2变体的抗体

2024-12-010
OAAI
BCG vaccination of healthcare workers for protection against COVID-19: 12-month outcomes from an international randomised controlled trial

医护人员接种卡介苗预防新型冠状病毒肺炎: 一项国际随机对照试验的12个月结果

2024-10-011
OAAI
Hepatitis C Virus Antiviral Drug Resistance and Salvage Therapy Outcomes Across Australia
2024-03-181
OAAI
Bacillus Calmette-Guerin vaccination for protection against recurrent herpes labialis: a nested randomised controlled trial
2023-10-012
OAAI
Emergence and antibody evasion of BQ, BA.2.75 and SARS- CoV-2 recombinant sub-lineages in the face of maturing antibody breadth at the population level

面对人群水平上成熟的抗体广度,BQ,BA.2.75和传染性非典型肺炎CoV-2的重组亚谱系的出现和抗体逃逸

2023-04-0121
OAAI
Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals
2022-05-0128
OAAI